Vanguard Asset Management
GLUE icon

Vanguard Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Vanguard Asset Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$816K Buy
33,732
+13,271
+65% +$251K ﹤0.01% 1986
2026
Q1 		$337K Buy
+20,461
New +$391K ﹤0.01% 2262

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Asset Management's GLUE Position: Q2 2026 in Review

Vanguard Asset Management increased its Monte Rosa Therapeutics (GLUE) stake by 65% in Q2 2026, buying an estimated $251K and bringing the position to 33,732 shares worth $816K. The position accounts for ﹤0.01% of the portfolio, ranked #1986.

Vanguard Asset Management first reported a position in GLUE in Q1 2026 and has held it in 2 quarters since. 175 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Vanguard Asset Management held 33,732 shares of Monte Rosa Therapeutics worth $816K as of Q2 2026.
  • Vanguard Asset Management bought 13,271 Monte Rosa Therapeutics shares in Q2 2026, an estimated $251K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1986 holding.
  • Vanguard Asset Management first reported a position in Monte Rosa Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 175 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.